Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
종목 코드 RENB
회사 이름Lunai Bioworks Inc
상장일Nov 18, 2014
CEOWeinstein (David)
직원 수- -
유형Ordinary Share
회계 연도 종료Nov 18
주소2080 Century Park East, Suite 906
도시LOS ANGELES
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호90067
전화14539179840
웹사이트
종목 코드 RENB
상장일Nov 18, 2014
CEOWeinstein (David)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음